Wikisage, the free encyclopedia of the second generation, is digital heritage

Difference between revisions of "Belzutifan"

From Wikisage
Jump to navigation Jump to search
(File:Vhl n1.jpg)
(External links)
Line 17: Line 17:
  
 
==External links==
 
==External links==
[[https://www.karger.com/Article/FullText/431323 Ben-Skowronek I, Kozaczuk S]] 2015: Von Hippel-Lindau Syndrome. Horm Res Paediatr 84:145-152. doi: 10.1159/000431323
+
[https://www.karger.com/Article/FullText/431323 Ben-Skowronek I, Kozaczuk S] 2015: Von Hippel-Lindau Syndrome. Horm Res Paediatr 84:145-152. doi: 10.1159/000431323
  
 
{{wikidata|Q27456641}}
 
{{wikidata|Q27456641}}

Revision as of 23:53, 13 August 2021

Belzutifan is a drug being approved for the treatment of renal cell carcinoma associated with von Hippel-Lindau disease.

Belzutifan is an inhibitor of hypoxia-inducible factor 2 alpha (HIF-2α).

Belzutifan is the first drug to be awarded an "innovation passport" by the UK Medicines and Healthcare products Regulatory Agency (MHRA)[1]

ATC

none

Belzutifan.png
belzutifan

Buecher Regal 636.jpg Retinal angioma associated with cerebellar angioma and sometimes angioma in other organs[2]

VHL protein

External links

Ben-Skowronek I, Kozaczuk S 2015: Von Hippel-Lindau Syndrome. Horm Res Paediatr 84:145-152. doi: 10.1159/000431323

Q27456641 op Wikidata  Interwiki via Wikidata


References

References: